ParagraphFour.com
Inter Partes Review List
(IPR's 2025– filed 10/1/2024 to 9/30/2025)

25-00033 10/28/2024 -- 11,744,802 Biktarvy®(bictegravir, emtricitabine and tenofovir) Tablets
25-00210 11/18/2024 -- 11,298,349 Cabometyx®(cabozantinib) Tablets
25-00427 11/18/2024 -- 12,128,039 Cabometyx®(cabozantinib) Tablets
25-00464 1/17/2025 -- 8,895,546 Valtoco®(diazepam) Nasal Spray
25-00465 1/17/2025 -- 11,241,414 Valtoco®(diazepam) Nasal Spray
25-00464 1/17/2025 -- 11,793,786 Valtoco®(diazepam) Nasal Spray
25-00505 1/17/2025 -- 11,344,552 Onivyde®(ironotecan) Injection
25-00514 1/30/2025 -- 7,919,499 Vivitrol®(naltrexone) Extended-release Injectable Suspension
25-00945 5/1/2025 -- 8,623,826 Akynzeo®(fosnetupitant and palonosetron) Solution in SDV
25-00946 5/1/2025 -- 9,186,357 Akynzeo®(fosnetupitant and palonosetron) Solution in SDV
25-00947 5/1/2025 -- 9,186,357 Akynzeo®(fosnetupitant and palonosetron) Solution in SDV
25-00948 5/1/2025 -- 9,943,515 Akynzeo®(fosnetupitant and palonosetron) Solution in SDV
25-00949 5/1/2025 -- 10,828,297 Akynzeo®(fosnetupitant and palonosetron) Solution in SDV
25-01139 6/20/2025 -- 8,268,847 Opsumit®(macitentan) Tablets
25-01531 9/12/2025 -- 11,344,552 Onivyde®(ironotecan) Injection